Please login to the form below

Not currently logged in

MIT chief financial officer joins Moderna Therapeutics

Israel Ruiz to serve as audit committee chair on its board of directors

US-based biotech Moderna Therapeutics has appointed Israel Ruiz to its board of directors to serve as audit committee chair.

Ruiz is currently executive vice president, treasurer and chief financial officer at Massachusetts Institute of Technology (MIT), where he is responsible for leading all of the institute's administrative and financial operations.

Before taking on his current role in 2011, Ruiz held a number of leadership positions at MIT, including vice president of finance, and lead the institute's digital learning technologies drive.

Ruiz also serves as audit committee chair on Fortive's board of directors, an industrial growth technology specialist.

Dr Noubar Afeyan, co-founder and chairman of Moderna Therapeutics, said: “We are delighted to welcome Israel to Moderna's board of directors.

“His progressive leadership at MIT has helped ensure the continued, unparalleled contributions of the institute on a regional, national and global scale, through education, innovation and entrepreneurship.

“We look forward to leveraging Israel's insights as Moderna evolves into a leading, clinical stage biotechnology company by harnessing the promise of messenger RNA science to improve lives.”

1st March 2017

From: Sales



Featured jobs

Subscribe to our email news alerts


Add my company
VCCP Health

We’re the challenger agency for challenger brands. Brands with a point to prove. Rx, OTC and wellness brands run by...

Latest intelligence

Waking the sleeping giant
The lights are coming on for healthcare delivery in Africa...
How to get rep buy-in for multi-channel
How do you manage a team who may be resistant to change?...
Blog: Digital therapeutics: within our reach?
Digital therapeutics is a hot topic right now. By using digital technology to manage, treat or even prevent chronic conditions, digital therapeutics is promising to revolutionise healthcare. But is this...